While many peri- and post-menopausal women request bioidentical hormones, there is no data to suggest that bioidential hormones are safer or more effective than FDA-approved hormone replacement therapies.
The FDA accepted a New Drug Application for fezolinetant, a novel, nonhormonal selective neurokinin-3 receptor (NK3R) antagonist for the treatment of menopause-related vasomotor symptoms.
The transition to menopause, or perimenopause, represents the passage from reproductive to non-reproductive life. During the perimenopause, women experience irregular menstrual cycles, which reflect the large fluctuations in ovarian hormone [...]
Although most women transition to menopause without experiencing psychiatric problems, an estimated 20% experience depression at some point during the menopausal transition.
This article focuses on how GABA-ergic neurotransmitter systems may modulate the interaction between reproductive steroid and sex steroid systems, and sheds light on the role allopregnanolone may play in medicating vulnerability to depression.Â
In this episode of It’s Not a Crisis, Dr. Lee Cohen speaks with host Doryn Wallach about the struggles many women experience during the menopausal transition. For most women, menopausal symptoms are manageable, but for [...]
Women with schizophrenia may experience worsening of their symptoms as they transition into the menopause.Â
CBT is effective for the management of vasomotor symptoms, depression, and sleep in perimenopausal women.
Recent studies suggest that the burden of menopausal symptoms is greater than generally perceived. About 80% of women experience vasomotor symptoms (VMS) – hot flashes and night sweats — as they transition into the menopause [...]
Although it is widely accepted that perimenopausal women are at increased risk for depressive symptoms, little research exploring suicidality in mid-life women has been conducted. In the spirit of Suicide Prevention Month, we will review [...]
